Form 4: Olema Pharmaceuticals Director Cyrus Harmon Sells 20,000 Shares

Director Cyrus Harmon of Olema Pharmaceuticals sold 20,000 shares of common stock on June 28, 2024, at a weighted average price of $10.77, pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• On June 28, 2024, Cyrus Harmon, a director of Olema Pharmaceuticals, sold 20,000 shares of common stock.
• The sale was executed at a weighted average price of $10.77, with prices ranging from $10.55 to $11.21.
• The transaction was conducted under a 10b5-1 trading plan adopted on May 16, 2023.
• Following the transaction, Harmon directly owns 761,283 shares and indirectly owns 122,028 shares through Harmon Family Investors LLC.
• Shane Kovacs, Attorney-in-Fact, signed the Form 4 on July 2, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The sale was conducted under a pre-arranged trading plan, suggesting it's not necessarily indicative of the director's negative outlook on the company. However, insider sales can sometimes create slight negative sentiment.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like directors and officers, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's valuation and future prospects. Sales by insiders can sometimes be interpreted negatively, but the existence of a pre-arranged 10b5-1 trading plan mitigates this concern as it indicates the transactions were planned well in advance.

Stakeholder Impact

• The sale of shares by a director could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates